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A B S T R A C T
A stable cell-line was established that expressed the recombinant avian antibody (rAb) against the infectious
bursal disease virus (IBDV). rAb exhibited neutralization activity to IBDV-B87 strain in DF1 cells. The minimum
rAb concentration required for inhibition of the cytopathic effect (CPE) was 1.563 μg/mL. To test the efficacy of
rAb, a 168-h cohabitation challenge experiment was performed to transmit the disease from the chickens
challenged with vvIBDV (HLJ0504 strain) to three test groups of chickens, i.e. (1) chickens treated with rAb, (2)
chickens treated with yolk antibody, and (3) non-treatment chickens. The survival rates of chickens treated with
rAb, yolk antibody and without treatment were 73%, 67% and 20%, respectively. Another batch of chickens was
challenged with IBDV (BC6/85 strain) and then injected with rAb (1.0 mg/kg) 6, 24 and 36 h post-challenge.
Non-treatment chickens had 100% morbidity, whereas those administered with rAb exhibited only 20%
morbidity. Morbidity was evaluated using clinical indicators and bursal histopathological section. This study
provides a new approach to treating IBDV and the rAb represents a promising candidate for this IBDV therapy.
1. Introduction
Infectious bursal disease (IBD) is considered to be one of the most
important diseases threatening the global poultry industry (Sapats
et al., 2003). IBD is caused by infectious bursal disease virus (IBDV),
which is a double-strand RNA virus belonging to the Birnaviridae family
(Berg, 2000; Eterradossi and Saif, 2008). IBDV replicates specifically in
developing B-lymphoid cells, resulting in the destruction of the
precursors of antibody-producing B cells in the bursal of Fabricius.
Consequently, the developing immunosuppression leads to vaccination
failures and susceptibility to other infections and diseases (Lukert and
Saif, 1997). Because of the prevalence of very virulent IBDV, and
treatment of IBDV is not extremely important. Prophylaxis (here
vaccination) is indeed extremely important. Treatment is an exception
in the poultry industry due to the high costs associated with it. (Malik
et al., 2006; Corley and Giambrone, 2002). Vaccination is the most used
measure to fight infections with IBDV (Deb et al., 2015). Antibody
treatment against IBDV is not widely used. It has been shown
experimentally already in the 1970′ that IBD could be prevented by
passive immunity (transfer of antibodies from a vaccinated to a non-
vaccinated chicken). It might be possible that there are some products
in the market (not to the referee's knowledge). But it is not widely used
(Lucio and Hitchner, 1980). Therapeutic antibody treatment is cur-
rently an effective prophylaxis and treatment of IBDV (Malik et al.,
2006).Chicken egg yolk antibody, referred to as immunoglobulin Y
(IgY), is now widely used to prevent and treat IBD, especially as it
possesses other advantages including cost-effectiveness, convenience
and high yield (Carlander et al., 2000). However, using yolk antibodies
http://dx.doi.org/10.1016/j.rvsc.2017.04.003
Received 21 September 2016; Received in revised form 8 March 2017; Accepted 7 April 2017
⁎ Correspondence to: H. Yang, College of Veterinary Medicine, China Agricultural University, Beijing 100193, PR China.
⁎⁎ Correspondence to: X. Wang, Harbin Veterinary Research Institute, Harbin 150001, PR China
⁎⁎⁎ Correspondence to: D. Li, College of Life Science, Northeast Agricultural University, Harbin 150030, PR China.
E-mail addresses: yanghanchun1@cau.edu.cn (H. Yang), xmw@hvri.ac.cn (X. Wang), 969670912@qq.com (D. Li).
Research in Veterinary Science 114 (2017) 194–201
0034-5288/ © 2017 Elsevier Ltd. All rights reserved.
MARK
in the prophylaxis and treatment of IBDV infection has some short-
comings, such as the potential risk of transmitting the infectious disease
and the low concentration of the specific antibody against IBDV in egg
yolk (2%–10%) (Mine and Kovacs-Nolan, 2002; Schade et al., 1996).It
is therefore imperative to develop new approaches to replace the yolk-
derived antibodies for the prophylaxis and treatment of IBD.
Genetic engineering provides strategies for the production of
recombinant antibodies. Recently, the field of recombinant antibodies
has rapidly progressed because of the interest in their therapeutic use.
Recombinant antibodies have many advantages (Sapats et al., 2003).
First, there is no concern for the contamination of infectious pathogens
during the production process. Second, specific and monoclonal anti-
bodies with high affinity can be obtained by gene manipulation
technology. Third, the manufacturing process and quality control
procedures can be easily established. Therefore, recombinant antibo-
dies from chickens may be an option to treat IBD. In a previous study
(Xu et al., 2014), we constructed highly diverse recombinant antibody
libraries from the spleens of immunized chickens, and single chain
fragment variable (scFv) antibodies against IBDV were isolated from an
antibody library. Finally, one IBDV-specific scFv isolated from the
library was able to neutralize the virus in vitro. Although scFv has the
advantages of lower immunogenicity and better tissue penetration
(Yokota et al., 1992), the half-life reduces in vivo because of the lack
of an Fc domain in the scFv structure. Moreover, the affinity of an
original antibody was sometimes impaired in the corresponding scFv
(Jiang et al., 2002; Miyashita et al., 1997). For these reasons, it is
preferable to use the full-length antibody which can persist for weeks in
the serum compared to the scFv. The objective of this study was to
obtain the full-length antibody which against the infectious bursal
disease virus.
2. Materials and methods
2.1. Viruses, cells and plasmids
The virus vaccine strains (GT, NF8, 1–65, BJ836, MB and B87) were
purchased from the Harbin Pharmaceutical Group Holding Co., Ltd. The
virus strain vvIBDV HLJ0504 was maintained in the Harbin Veterinary
Research Institute (HVRI) (Chinese Academy of Agricultural Science,
China). The virus strain IBDV BC6/85 strain was provided by the QYH
Biotech Company Limited. The DF1 cell line, Chinese hamster ovary
(CHO-K1-SV) cell line, Pkappa vector and pBSD-scFv plasmid (contain-
ing VH and VL gene fragments of the anti-IBDV neutralization antibody)
were laboratory stock (Xu et al., 2014). Pee6.4 and Pee12.4 eukaryotic
expression plasmids (containing glutamine synthetase (GS) gene, a
selectable marker) were purchased from Lonza, Switzerland.
2.2. Antibodies and antigen
The HRP-goat anti-chicken antibody was purchased from
eBioscienc. The anti-IBDV egg yolk antibody was purchased from
Pulike Biological Engineering, INC. The VP2 protein was expressed in
E. coli (unpublished data) and purified by an AKTA Purifer 100 (GE,
USA).
2.3. Primers
2.4. Animals
One-hundred and thirty (130), 21-day-old specific pathogen free
(SPF) chickens were purchased from the HVRI and housed in negative-
pressure-filtered air isolators. Animal experiments were approved by
the Animal Ethics Committee of the Institute.
2.5. Reagents
DNA markers and restriction enzymes were purchased from
TaKaRa. Protein marker was purchased from Fermentas. Dulbecco's
modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were
purchased from Gibco. Serum free media was purchased from WISENT,
INC.
2.6. Construction of plasmid which contains genes of recombinant avian
antibody
The VL (Variable region of light chain) and VH (Variable region of
heavy chain) genes of the recombinant avian antibody were amplified
by PCR from plasmid pBSD-scFv with two pairs of primers (VLF, VLR
and VHF, VHR). The CL (Constant region of light chain) gene of the
recombinant avian antibody was synthesized according to the se-
quences published in GenBank (accession numbers of K00678) and
confirmed by sequencing. The CH (Constant region of heavy chain) gene
of recombinant avian antibody was synthesized according to the
sequences published in GenBank (accession numbers of ×07174) and
confirmed by sequencing. The CL gene and CH gene were synthesized in
Invitrogen (Beijing, China). Using enzyme digestion and ligation, the
recombinant expression vector was successfully constructed and named
Peedual-IRES (Fig. 1E). The strategy for the construction of rAb was
showd as below (Fig. 1).
2.7. Screening the cell-line exhibiting high expression of recombinant avian
antibody
The Peedual-IRES plasmid containing the genes of rAb was trans-
Table 1
Primers used in the amplification of the target genes.
Primers Primer sequences(5′-3′)
VHF GGATCC ACTGGTGCCGTGACGTTGGACGAG(BamH I)
VHR GCTAGCGGAGGAGACGATGACTTCGGTCC(Nhe I)
CHF GCTAGCGCGAGCCCCACATCGCCCCCCCGAT(Nhe I)
CHR
VLF
VLR
CLF
CLR
EGFPR
GAATTCATTA TTTACCAGCCTGTTTCTGCAGCGTG(EcoR I)
GGATCCACTGGTGCGCTGACTCAGCCGTCCTCGGTGTC(BamH I)
TGATGGTGGGGGCCACCTTGGGCTGACCTAGGACGGTCAGGG
CGGGACAACCCTGACCGTCCTAGGTCAGCCCAAGGTGGCCCCCACCATCA
GCTAGCATTAGCACTCGGACCTCTTCAGGGTCTTC(Nhe I)
GAATTCTTACTTGTACAGCTCGTCCATG(EcoR I)
Note: F means forward primer, R means reverse primer. Underline is shown as the restriction site of enzyme. The primers were synthesized by
Invitrogen (Beijing, China).
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fected into CHO-K1-SV cells. As the plasmid contained the glutamine
synthetase (GS, GS is the enzyme responsible for the biosynthesis of
glutamine using glutamate and ammonia as substrates) gene and the
EGFP gene (as the selectable markers), these two selectable markers
were used to screen the cell-line exhibiting a high expression of rAb.
The cells were cultured in selective medium (containing methionine
sulphoximine (MSX) which selectively inhibits the activity of the GS
gene) for 3 weeks, thereby killing most of the artificial GS-gene
negative cells. The surviving cells were observed for their fluorescence
intensity because of the EGFP, using a fluorescence microscope.
Fig. 1. The schematic diagram of Peedual-IRES vector construction. A The gene of the L chain containing the kappaleader signal sequence and the gene of the IRES-EGFP fragment were
inserted into the Pee12.4 vector; B.The gene of the H chain containing the kappaleader signal sequence was inserted into the Pee6.4 vector; C The Pee12.4 vector was digested with
enzymes “Sal I, Not I”; D The Pee6.4 vector was digested with enzymes “Sal I, Not I”; E Fragments which contained the L and H genes of the recombinant avian antibody were ligated and
the recombinant expression vector named Peedual-IRES.
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Fluorescence intensity among the monoclonal cell lines is not homo-
geneous, and stronger fluorescence intensity indicates a stronger ability
of cells to express exogenous genes. Therefore, flow cytometer methods
(FCM) were used to further screen the cells exhibiting a high expression
of rAb.
2.8. The expression of recombinant avian antibody
Cells exhibiting a high expression of rAb were cultured in serum-
free medium. The supernatant was collected every three days and the
supernatant centrifuged and condensed by a hollow fiber column (GE,
USA) (HFC).
2.9. Western blotting
The VP2 protein was subjected to SDS-PAGE, and transferred onto a
nitrocellulose membrane. The membrane was blocked with 5% (w/v)
skimmed milk in PBS buffer. The membrane was incubated with 100 μL
rAb (40 μg/mL) in PBS at 4 °C overnight, then incubated with HRP-goat
anti-chicken antibody (1:7500) for 1 h at 37 °C. The membrane was
developed using an ECL detection system.
2.10. Relative specifically analysis of recombinant avian antibody
To measured a concentration dependent reactivity (ability to be
detected) of the rAb with a given amount of VP2, 96-well immunoassay
plates were coated with VP2 protein (40 μg/mL) overnight at 4 °C. The
wells were blocked with TBS blocking buffer for 2 h at 37 °C (250 μL/
well), and 100 μL rAb at several concentrations (400, 80, 16 and
3.2 μg/mL) was added into the wells in triplicate. The 96-well plates
were incubated at 37 °C for 1 h then washed with TBST followed by
incubation with HRP-goat anti-chicken antibody (1:7500) in TBS
blocking buffer. Three negative controls were included: Negative 1
(the supernatant of the serum-free medium culturing CHO-K1-SV cells
with no transfection), Negative 2 (without rAb) and Negative 3 (with-
out HRP-goat anti-chicken antibody).
To qualitative assay (positive/negative) between rAb and different
IBDV vaccine strains, 96-well immunoassay plates were coated with
different IBDV vaccine strains (100TCID50) overnight at 4 °C. Wells
were blocked with TBS blocking buffer for 2 h at 37 °C (250 μL/well).
100 μL/well of rAb (400 μg/mL) was added into the wells in triplicate,
then incubated at 37 °C for 1 h. Plates were washed with TBST and
incubated with HRP-goat anti-chicken antibody (1:7500) in TBS block-
ing buffer at 37 °C for 1 h. Two negative controls were included:
Negative 1 (the supernatant of the serum-free medium culturing
CHO-K1-SV cells with no transfection), and Negative 2 (Newcastle
Disease Virus (NDV)). Two assays were developed using TMB solution.
The development of color product was terminated by 50 μL of 0.1 mol/
LH2SO4. The absorbance of each well was measured with an ELISA
reader (BioeRad type 680) at 450 nm.
2.11. The titer of IBDV
The chicken embryo fibroblasts cells (DF1 cells) were cultured in
DMEM medium containing 10% FBS. IBDV, derived by passaging of
IBDV vaccinate (B87 strain, 100 μL) in chicken embryo, was diluted
with DMEM. The logarithmic phase DF1 cells were transferred to flat-
bottom, 96-well plates (100 μL in each well) and the monolayer DF1
cells treated with Log2 dilution of IBDV (100 μL in each well), then
incubated at 37 °C in the presence of 5% CO2. The cell monolayers were
examined visually for a cytopathic effect after 7d. The cells of the
control were treated in the same way with 100 μL DMEM. Samples were
measured in eight replicates and each experiment was repeated at least
twice. The 50% tissue culture infective dose (TCID50) of virus was
calculated by the Reed-Muench method (Reed and Muench, 1938).
2.12. The recombinant avian antibody neutralization test
rAb (100 μL) with different concentrations (400 to 0.782 μg/mL)
were incubated with 100 TCID50 of IBDV (100 μL) at 37 °C for 1 h. The
rAb-virus mixture was then incubated with the DF1 monolayers in 96-
well plates at 37 °C in the presence of 5% CO2. The positive control
group was treated with IBDV (100 TCID50, 100 μL) and DMEM (100 μL).
The negative control group was treated with DMEM (200 μL). A virus
back-titration was performed to assess the actual virus titer used in
experiment. CPE was observed using an inverted microscope on day 7
post-inoculation, and the samples measured in eight replicates.
2.13. The half-life of the recombinant avian antibody in vivo
Thirty (30) 21-one-day-old SPF chickens were randomly divided
into three groups, i.e., rAb, yolk antibody (yAb), and the saline group,
each with 10 chickens. The chickens were injected with 1.0 mg/kg rAb
and yAb intramuscularly. On Days 1, 4, 7, 10, 13 and 16 post-injection,
1.0 mL of blood was collected from each chicken and ELISA used to
measure the contents of rAb and yAb in the serum. Briefly, 96-well
immunoassay plates were coated with VP2 protein (40 μg/mL) over-
night at 4 °C. The wells were blocked with TBS blocking buffer for 2 h at
37 °C (250 μL/well), and the serum of PBS group, yolk antibody group
and rAb group collected in different time-phase was added into the
wells in triplicate, then incubation with HRP-goat anti-chicken anti-
body (1:7500) in TBS blocking buffer. The serum collected on day 0 was
used as negative control. The assay was developed using TMB solution.
The development of color product was terminated by 50 μL of 0.1 mol/
LH2SO4. The absorbance of each well was measured with an ELISA
reader (BioeRad type 680) at 450 nm.
2.14. The cohabitation challenge experiment in chickens
A total of 60, 21-one-day-old SPF chickens were randomly divided
into four groups, each with 15 chickens, i.e. the model control group
(challenged with HLJ0504 strains with 0.2 × 103 ELD50), the rAb
treatment group (injected with 1.0 mg/kg rAb intramuscularly), the
yolk antibody (yAb) treatment group (injected with 1.0 mg/kg yAb
intramuscularly) and normal control (injected with PBS intramuscu-
larly). Chickens of the model control group were challenged with IBDV,
and chickens in the other groups were injected with rAb, yAb and PBS,
respectively. All of the chickens were housed together for 168 h, after
which the survival rate of each group was calculated.
2.15. The treatment experiment in chickens with IBD
Forty (40), 21-one-day-old SPF chickens were randomly divided
into four groups each with 10 chickens, i.e. the model control group,
rAb treatment group, yolk antibody (yAb) treatment group and normal
control group (unchallenged and non-treatment). The chickens of each
group were housed in separate negative-pressure-isolators. During the
experiment, chickens of the model control group, rAb treatment group
and yAb treatment group were challenged with BC6/85 strain with
0.2 × 104 BID50 at 21-days-of-age. The rAb and yAb chickens were
injected 6, 24 and 36 h post-challenge (1.0 mg/kg intramuscularly)
then sacrificed 72 h post-challenge. Bursale were weighed and the
bursall/body weight ratio (BF/BW) calculated. Bursal lesion scores
were given to each chicken based on the increasing severity of bursall
atrophy (0 = no lesion, 1 = slight change, 2 = scattered or partial
bursall damage, 3 = 50% or less follicle damage, 4 = 51–75% follicle
damage, 5 = 76–100% bursall damage) (Li et al., 2013; Shaw and
Davison, 2000).A chicken with a bursall lesion score of 1 and a BF/BW
ratio of not< 2 standard deviations (S.D.) below the average ratio of
the normal control group was defined as having been protected against
the IBDV challenge.
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2.16. Statistical analysis
All experimental data were analyzed by one-way analysis of
variance (ANOVA) followed by the Students two-tailed t-test using
SPSS13.0 software. P < 0.05 was deemed to indicate statistical
significance of differences.
3. Results
3.1. Plasmid of recombinant avian antibody construction
The correct sequences of the L and H chain contained by the
recombinant expression vector (Peedual-IRES) were confirmed by DNA
sequencing (data not show).
3.2. Screening of the cells with high expression of recombinant avian
antibody
Non-recombinant cells were killed by culturing in selective medium.
Also, cells with high expression of EGFP were selected by flow
cytometric analysis. The fluorescence intensity increased to 10.5, 42.0
and 94.9% after the first, second and third round of screening,
respectively (Fig.2).
3.3. The expression and identification of recombinant avian antibody
SDS-PAGE analysis showed that the cells expressed the H chain
protein of rAb (approximately 66 kDa), and the L chain protein of rAb
(approximately 25 kDa). The rAb reacted with VP2 protein specifically
(Fig. 3A, B).
3.4. The recombinant avian antibody titers to VP2 or different IBDV vaccine
strains by ELISA
The ELISA showed that an antibody concentration of 3.2 μg/mL was
still able to detected 40 μg/mL VP2 bound to the plate and the rAb can
react to different IBDV vaccine strains bound to the plate compared
with Negative 1 (Fig. 4).
3.5. The titer of IBDV
The numbers of DF1 cells with cytopathic effect (CPE) were showed
as blew (Table 2), the 50% tissue culture infective dose (TCID50) of the
virus was calculated by the Reed-Muench method, TCID50 = 106.4/
0.1 mL.
3.6. The neutralization activity of recombinant avian antibody to IBDV B87
strain
The rAb exhibited a high ability to neutralize 100 TCID50 of IBDV.
The minimum concentration of rAb, which completely suppressed CPE
induced by the virus in 8- of 8-wells, was 1.563 μg/mL (Table 3).
3.7. The half-life of recombinant avian antibody in vivo
The results showed that there was no significant difference between
the half-life of rAb and yAb (Fig. 5).
3.8. Survival rates in chickens challenged with vvIBDV
In the cohabitation challenge experiment, the survival rates of
chickens at 72 h post-challenge in the model control, rAb treatment
group, yAb treatment group and normal control were 93.3, 100, 100
Fig. 3. The expression and identification of recombinant avian antibody. SDS-PAGE was
used to analyse rAb in the supernatant; VP2 protein was subjected to SDS-PAGE and
transferred onto membrane, then the membrane was incubated with the supernatant of
the serum-free medium which cultured CHO-K1-SV cells transfected with or without the
eukaryotic expression plasmid (Peedual-IRES), followed by incubation with HRP-goat
anti-chicken antibody. (A) The expression of recombinant avian antibody; 1 The super-
natant of the serum-free medium which cultured CHO-K1-SV cells with no transfection; 2
The supernatant of the serum-free medium which cultured CHO-K1-SV cells transfected
with the eukaryotic expression plasmid (Peedual-IRES). (B) The identification of
recombinant avian antibody by western blotting. 1 Incubation with the supernatant of
the serum-free medium which cultured CHO-K1-SV cells transfected with the eukaryotic
expression plasmid; 2 Incubation with the supernatant of the serum-free medium which
cultured CHO-K1-SV cells without the eukaryotic expression plasmid.
Fig. 2. The cells with high expression of recombinant avian antibody were obtained by the screening of flow cytometer. The solid peaks represented rAb-transfected cells which expressed
EGFP. The hollow peaks represented cells without transfecting with recombinant plasmid which were used as negative controls. (A) The first round of screening. (B) The second round of
screening. (C) The third round of screening.
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and 100%, respectively, at 96 h post-challenge 73.3, 86.7, 93.3 and
80%, respectively, at 120 h 40, 80, 80 and 60%, respectively, at 144 h
post-challenge 13.3, 80, 80 and 53.3% respectively, and at 168 h post-
challenge 6, 73, 67 and 20%, respectively (Fig. 6).
3.9. Protection against IBDV challenge
The BF/BW ratios, bursal lesion scores and protection rate are
presented in Table 4. Chickens in the normal control group remained
healthy and had normal sized bursale. After the IBDV challenge, the BF/
BW ratio in the model control group (2.62 ± 0.34) decreased sig-
nificantly compared to the normal control group (5.72 ± 0.44); BF/
BW ratio in the rAb treatment group was 4.65 ± 0.43, which was
increased significantly compared to the model control group and the
yAb treatment group (3.29 ± 0.21). Chickens in the model control
group exhibited typical clinical signs of the disease and a 100%
infection rate. The protection rate in the rAb treatment group was
Fig. 4. The recombinant avian antibody react to VP2 or different IBDV vaccine strains.
The plates were coated with VP2 protein or different IBDV vaccine strains, followed by
incubating with the supernatant of the serum-free medium which cultured CHO-K1-SV
cells transfected with the eukaryotic expression plasmid (Peedual-IRES). The absorbance
of each well was measured with ELISA reader at UV wave length of 450 nm. The data are
the means± S.D. of quadruplex samples. (A) The specifically of rAb (400 μg/mL, 80 μg/
mL, 16 μg/mL, 3.2 μg/mL) to VP2 protein. (B) The specifically of rAb to different IBDV
vaccine strains.Note: ⁎⁎P < 0.01 vs Negative 1.
Fig. 5. The half-life of recombinant avian antibody in vivo. 30 twenty-one-day-old SPF
chickens were randomly divided into 3 groups: rAb group, yolk antibody (yAb) group and
saline group. Each group contained 10 chickens. The chickens were injected with rAb and
yolk antibody intramuscularly at a dose of 1 mg/kg. Blood was drawn from each chicken
on day 0, day 1, day 4, day 7, day 10, day 13 and day 16 after injection. The blood was
centrifuged to obtain serum. ELISA was used to measure the contents of rAb and yolk
antibody.Note: ⁎P < 0.05 vs the Day 0 (n= 3), ⁎⁎P < 0.01 vs the Day 0(n= 3).
Fig. 6. The survial rates in the cohabitation challenge experiment. In this experiment,
chickens of model control group were challenged with vvIBDV (HLJ0504 strain), and
chickens in other groups were injected with rAb, yAb and PBS simultaneously,
respectively. Then all of chickens cohabitated for 168 h, and the survival rates of each
group were caculated.
Table 2
The numbers of wells with cytopathic effect (CPE).
Dilution of virus The number of CPE The number of non-CPE
101 8 0
102 8 0
103 8 0
104 8 0
105 8 0
106 5 3
107 2 6
108 0 8
109 0 8
1010 0 8
1011 0 8
The IBDV (B87 strains) was diluted by DMEM. The samples were measured in 8 replicates,
data were obtained from three independent experiments.
Table 3
The neutralization activity of recombinant avian antibody to IBDV (B87 strain).
Concentration of rAb(μg/mL) The cell with CPE or non-CPE
rAb DMEM IBDV
400 – – +
200 – – +
100 – – +
50 – – +
25 – – +
12.5 – – +
6.25 – – +
3.125 – – +
1.563 – – +
0.782 + – +
+: Cytopathic effects observed, − No cytopathic effects detected. The samples were
measured in 8 replicates, and data were obtained from three independent experiments.
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80%, whereas the protection rate in the yAb treatment group was only
40%. Together, these data showed that the rAb had a good efficacy in
treating IBD.
4. Discussion
Infectious bursal disease virus is a pathogen of major economic
importance in the poultry industry. In this study, we use the genetic
engineering technology to create recombinant antibody against IBDV.
As we know, the research and development of therapeutic antibodies is
a rapidly progressing field (Aggarwal, 2009; Beck et al., 2010).In the
past 30 years,> 30 immunoglobulins (IgGs) and their derivatives have
been approved for use, such as infliximab, rituximab and trastuzumab
(Reichert, 2009a; Reichert, 2010). The antibody research has hinted at
the promise of new versatile therapeutic agents to fight cancer,
autoimmune diseases and infection. Technology development and the
testing of new generations of antibody reagents have altered our view
of how they might be used for prophylactic and therapeutic purposes.
The therapeutic antibodies of today are genetically engineered mole-
cules that are designed to ensure high specificity and functionality
(Brekke and Sandlie, 2003). The use of biotechnology to create
therapeutic antibodies holds many advantages for the future. Phage-
display and bacterial-display technology are methods used for screen-
ing recombinant antibodies from antibody libraries. Currently, phage-
display technology is the major method for screening recombinant
antibodies from antibody libraries. However, phage-display is time
consuming, taking at least one year to obtain the desired antibodies. In
contrast, bacteria-display technology offers an efficient way to process
library screening with FCM to diminish the screening time and enable
real-time visualization to identify desired antibody clones (Dane et al.,
2006; Jung et al., 2007).
Therapeutic antibodies for human diseases like cancers, autoim-
mune diseases and virus infections are most frequently studied.
However, genetically engineered therapeutic antibodies for animal
diseases have not been reported. The present study describes a new
method that uses bacterial display isolates, scFv antibodies, against
IBDV from an antibody library via the VP2 protein (Xu et al., 2014). The
VP2 protein is a component of IBDV (Mundt et al., 1995). It has been
reported that the VP2 protein is the major protective antigen of the
virus and contains antigenic epitopes responsible for the induction of
neutralization antibodies (Becht et al., 1988). By using bacterial-
display, we obtained the scFv antibody with neutralization activity.
Based on the sequence of scFv antibody with neutralization activity, a
recombinant eukaryotic expression plasmid with double cistrons con-
taining the sequence of the rAb, was constructed. In addition, the
recombinant plasmid also contained the EGFP gene. FCM was used to
screen those cells exhibiting high expression of the rAb as determined
by EGFP. The CHO-K1SV cell line was chosen to produce the rAb. The
stable cell-line exhibiting high expression of the rAb was obtained after
three rounds of FCM screening. Finally, a eukaryotic expression system
that can be used for the rapid screening of eukaryotic cell lines
expressing recombinant avian antibody was developed.
Condensing by a hollow fiber column obtained a high concentration
of rAb. The relative affinity assay showed that the rAb could specifically
react with VP2 protein of the IBDV virulent strain and different IBDV
vaccine strains including the GT, NF8, 1–65, BJ836, MB and B87
strains. Moreover, the rAb exhibited high neutralization activity to
IBDV-B87 with a minimum concentration for the inhibition of CPE of
1.563 μg/mL. These results suggest that rAb has the potential to treat
IBD. The half-life of rAb in the serum was approximately seven days. A
cohabitation challenge experiment showed that administration of rAb
increased the survival rate compared to chickens without. Furthermore,
administration of rAb exhibited good efficacy and a high protection rate
(80%) compared to challenge chickens without treatment, and chal-
lenged chickens treated with yAb (their protection rate was only 40%).
These data indicate that rAb has the therapeutic efficacy to treat IBD.
In conclusion, a eukaryotic expression system was established which
was used for the rapid screening of a eukaryotic cell-line expressing
recombinant avian antibody. The recombinant avian antibody exhib-
ited high neutralization activity and good therapeutic efficacy, which
indicate that the recombinant avian antibody has the potential to be a
new therapeutic antibody in the treatment of IBD.
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